This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goorin, A. M. Articles by Link, M. P. Search for Related Content PubMed PubMed Citation Articles by Goorin, A. M. Articles by Link, M. P. Related Articles Related Correspondence Social Bookmarking                            What's this?

Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651

Allen M. Goorin, Douglas J. Schwartzentruber, Meenakshi Devidas, Mark C. Gebhardt, Alberto G. Ayala, Michael B. Harris, Lee J. Helman, Holcombe E. Grier, Michael P. Link

From the Department of Pediatrics, Dana-Farber Cancer Institute; Division of Medicine, Children’s Hospital Boston; Department of Pediatrics, Department of Orthopedic Surgery, Harvard Medical School; and Massachusetts General Hospital, Boston, MA; Surgical Oncology Branch and Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Statistics, University of Florida, and Pediatric Oncology Group Statistical Office, Gainesville, FL; Department of Surgical Pathology, University of Texas, and M.D. Anderson Cancer Center, Houston, TX; Tomorrows Children’s Institute, Hackensack, and University Medical Center and University of Medicine and Dentistry of New Jersey, Newark, NJ; and Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.

Address reprint requests to Allen M. Goorin, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; email: allen_goorin{at}dfci.harvard.edu.

Purpose: Successful therapeutic interventions to prevent disease progression in patients with nonmetastatic osteosarcoma have included surgery with adjuvant chemotherapy. Presurgical chemotherapy has been advocated for these patients because of putative improvement in event-free survival (EFS). The advantages of presurgical chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy. The contribution of chemotherapy and surgery timing has not been tested rigorously.

Patients and Methods: Between 1986 and 1993, we conducted a prospective trial in patients with nonmetastatic osteosarcoma who were assigned randomly to immediate surgery or presurgical chemotherapy. Except for the timing of surgery (week 0 or 10), patients received 44 weeks of identical combination chemotherapy that included high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin, bleomycin, cyclophosphamide, and dactinomycin.

Results: One hundred six patients were enrolled onto this study. Six were excluded from analysis. Of the remaining 100 patients, 45 were randomly assigned to immediate chemotherapy, and 55 were randomly assigned to immediate surgery. Sixty-seven patients remain disease-free. At 5 years, the projected EFS ± SE is 65% ± 6% (69% ± 8% for immediate surgery and 61% ± 8% for presurgical chemotherapy; P = .8). The treatment arms had similar incidence of limb salvage (55% for immediate surgery and 50% for presurgical chemotherapy).

Conclusion: Chemotherapy was effective in both treatment groups. There was no advantage in EFS for patients given presurgical chemotherapy.

Supported in part by grant nos. CA-03161, CA-05587, CA-11233, CA-15525, CA-15898, CA-20549, CA-25408, CA-28383, CA-28439, CA-28476, CA-29139, CA-29293, CA-30969, CA-32053, CA-33587, CA-33603, CA-33625, CA-41573, CA-69177, and CA-69428 from the National Institutes of Health, Bethesda, MD.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Preoperative Therapy Versus Immediate Surgery in Nonmetastatic Osteosarcoma
  G. Bacci, S. Ferrari, A. Longhi, C. Forni, P. Ruggieri, A. Briccoli, M. De Paolis, and E. Setola
  JCO 2003 21: 4662-4663 [Full Text]
• Surgical Expertise and Outcome in Osteosarcoma Trials
  Stefan S. Bielack and Heribert Jürgens
  JCO 2004 22: 2511 [Full Text]

This article has been cited by other articles:

				S. Bielack, D. Carrle, P. G. Casali, and On behalf of the ESMO Guidelines Working Group Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv137 - iv139. [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, Z. Chen, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2057 - 2062. [Abstract] [Full Text] [PDF]

				G. J. C. Myers, A. T. Abudu, S. R. Carter, R. M. Tillman, and R. J. Grimer Endoprosthetic replacement of the distal femur for bone tumours: LONG-TERM RESULTS J Bone Joint Surg Br, April 1, 2007; 89-B(4): 521 - 526. [Abstract] [Full Text] [PDF]

				A. S. Petrilli, B. de Camargo, V. O. Filho, P. Bruniera, A. L. Brunetto, R. Jesus-Garcia, O. P. Camargo, W. Pena, P. Pericles, A. Davi, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival J. Clin. Oncol., March 1, 2006; 24(7): 1161 - 1168. [Abstract] [Full Text] [PDF]

				J. G. Wright and M. C. Gebhardt Multicenter Clinical Trials in Orthopaedics: Time for Musculoskeletal Specialty Societies to Take Action J. Bone Joint Surg. Am., January 1, 2005; 87(1): 214 - 217. [Full Text] [PDF]

				N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]

				S. S. Bielack and H. Jurgens Surgical Expertise and Outcome in Osteosarcoma Trials J. Clin. Oncol., June 15, 2004; 22(12): 2511 - 2511. [Full Text] [PDF]

				G. Bacci, A. Longhi, C. Forni, P. Ruggieri, A. Briccoli, M. De Paolis, and E. Setola In Reply: J. Clin. Oncol., June 15, 2004; 22(12): 2511 - 2513. [Full Text]

				G. Bacci, S. Ferrari, A. Longhi, C. Forni, P. Ruggieri, A. Briccoli, M. De Paolis, and E. Setola Preoperative Therapy Versus Immediate Surgery in Nonmetastatic Osteosarcoma J. Clin. Oncol., December 15, 2003; 21(24): 4662 - 4663. [Full Text] [PDF]